Real-time funding, M&A, exec moves & hiring — the signals that move deals
The intelligence a $25K terminal charges for — the day it breaks, in your market, at a fraction of the price.
Loading live signals…
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
Executive ChangeItem 5.02 · 8-KLOW RiskPositive
MYRIAD GENETICS, INC.
Filed: Jun 4, 2026CIK: 0000899923
AI Executive Summary
AI-powered analysis of 8-K filing content
Myriad Genetics stockholders approved an amendment to the 2012 Employee Stock Purchase Plan on June 4, 2026, authorizing an additional 4,000,000 shares for issuance. This action reflects the company's commitment to employee retention and engagement through enhanced equity compensation.
Key Takeaways
4,000,000 additional shares authorized under the 2012 Employee Stock Purchase Plan
Amendment approved at the 2026 Annual Meeting of Stockholders on June 4, 2026
2 more takeaways
Filing Overview
Form Type8-K
Filing DateJun 4, 2026
Item5.02
CategoryExecutive Change
CIK0000899923
Accession #mygn-20260604
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
stock offering
What This Means
A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.